BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 15510610)

  • 1. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
    Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
    Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
    Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
    Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
    Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
    Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.
    Hernández MV; Peris P; Guañabens N; Alvarez L; Monegal A; Pons F; Ponce A; Muñoz-Gómez J
    Calcif Tissue Int; 1997 Jul; 61(1):48-51. PubMed ID: 9192513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) for diagnosis of bone metastasis in patients with primary lung cancer].
    Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
    Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):857-60. PubMed ID: 14727545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
    Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
    BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.
    Ueda M; Inaba M; Okuno S; Nagasue K; Kitatani K; Ishimura E; Shimizu M; Miki T; Kim M; Nishizawa Y
    Am J Kidney Dis; 2002 Oct; 40(4):802-9. PubMed ID: 12324916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.